Intermittent Fasting Resolves Dyslipidemia and Atherogenesis in Apolipoprotein E-Deficient Mice in a Diet-Dependent Manner, Irrespective of Sex

Cells. 2023 Feb 7;12(4):533. doi: 10.3390/cells12040533.

Abstract

In humans and animal models, intermittent fasting (IF) interventions promote body weight loss, improve metabolic health, and are thought to lower cardiovascular disease risk. However, there is a paucity of reports on the relevance of such nutritional interventions in the context of dyslipidemia and atherosclerotic cardiovascular diseases. The present study assessed the metabolic and atheroprotective effects of intermittent fasting intervention (IF) in atherosclerosis-prone apolipoprotein E-deficient (Apoe-/-) mice. Groups of male and female Apoe-/- mice were fed a regular (chow) or atherogenic (high-fat, high-cholesterol, HFCD) diet for 4 months, either ad libitum or in an alternate-day fasting manner. The results show that IF intervention improved glucose and lipid metabolism independently of sex. However, IF only decreased body weight gain in males fed chow diet and differentially modulated adipose tissue parameters and liver steatosis in a diet composition-dependent manner. Finally, IF prevented spontaneous aortic atherosclerotic lesion formation in mice fed chow diet, irrespective of sex, but failed to reduce HFCD-diet-induced atherosclerosis. Overall, the current work indicates that IF interventions can efficiently improve glucose homeostasis and treat atherogenic dyslipidemia, but a degree of caution is warranted with regard to the individual sex and the composition of the dietary regimen.

Keywords: adipose tissue; atherosclerosis; glucose tolerance; hepatic steatosis; intermittent fasting; reverse cholesterol transport.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoproteins
  • Apolipoproteins E
  • Atherosclerosis* / metabolism
  • Diet
  • Dyslipidemias* / metabolism
  • Female
  • Glucose
  • Humans
  • Hypercholesterolemia*
  • Hyperlipidemias*
  • Intermittent Fasting
  • Male
  • Mice

Substances

  • Glucose
  • Apolipoproteins E
  • Apolipoproteins

Grants and funding

This research was funded by the region Occitanie Pyrénées-Méditerranée (GRAINE HEPATOCARE, Reference number: no. 19014226). J.M. received a Ph.D. fellowship from Inserm and the Region Occitanie Pyrénées-Méditerranée (allocation doctorale, Reference number: no. R18093BB/RPH18007BBA).